Abstract
THE central pathological feature of human kidney disease that leads to kidney failure is the accumulation of extracellular matrix in glomeruli. Overexpression of transforming growth factor-β (TGF-β) underlies the accumulation of pathological matrix in experimental glomerulonephritis1. Administration of an antibody raised against TGF-β to glomerulonephritic rats suppresses glomerular matrix production and prevents matrix accumulation in the injured glomeruli2. One of the matrix components induced by TGF-β, the proteoglycan decorin, can bind TGF-β and neutralize its biological activity3, so decorin may be a natural regulator of TGF-β (refs 3,4). We tested whether decorin could antagonize the action of TGF-β in vivo using the experimental glomerulonephritis model1. We report here that administration of decorin inhibits the increased production of extracellular matrix and attenuates manifestations of disease, confirming our hypothesis. On the basis of our results, decorin may eventually prove to be clinically useful in diseases associated with overproduction of TGF-β.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Okuda, S., Languino, L. R., Ruoslahti, E. & Border, W. A. J. clin. Invest. 86, 453–462 (1990).
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B. & Ruoslahti, E. Nature 346, 371–374 (1990).
Yamaguichi, Y., Mann, D. M. & Ruoslahti, E. Nature 346, 281–284 (1990).
Border, W. A., Okuda, S., Languino, L. R. & Ruoslahti, E. Kidney Int. 37, 289–295 (1990).
Roberts, A. B. & Sporn, M. B. in The Handbook of Experimental Pharmacology (ed Sporn, M. B. & Roberts, A. B.) 419–472 (Springer, Heidelberg, 1989).
Oomura, A., Nakamura, T., Arakawa, M., Ooshima, A. & Isemura, M. Virchows Archs A. Pathol. Anat. 415, 151–159 (1989).
Balza, E., Borsi, L., Allemanni, G. & Zardi, L. FEBS Lett. 228, 42–44 (1988).
Wang, G., Cohen, D. S., Palmer, E. & Sheppard, D. J. biol. Chem. 266, 15598–15601 (1991).
Pearson, C. A., Pearson, D., Shibahara, S., Hofsteenge, J. & Chiquet-Ehrismann, R. EMBO J. 7, 2977–2981 (1988).
Ginsberg, J. M., Chang, B. S., Matarese, R. A. & Garella, S. New Engl. J. Med. 309, 1543–1550 (1983).
Border, W. A. & Ruoslahti, E. J. clin. Invest. 90, 1–7 (1992).
Connor, T. J. et al. J. clin. Invest. 83, 1661–1666 (1989).
Kulozik, M., Hogg, A., Lankat-Buttgereit, B. & Krieg, T. J. clin. Invest 86, 917–922 (1990).
Courtoy, P. J., Kanwar, Y. S., Hynes, R. O. & Farquar, M. G. J. Cell Biol. 87, 691–696 (1980).
Courtoy, P. J., Timpl, R. & Farquhar, M. G. J. Histochem. Cytochem. 30, 874–886 (1982).
Border, W. A. Kidney Int. 34, 419–434 (1988).
Choi, H. U., Johnson, T. L., Pal, S., Tang, L.-H. & Rosenberg, L. J. biol. Chem. 264, 2876–2884 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Border, W., Noble, N., Yamamoto, T. et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360, 361–364 (1992). https://doi.org/10.1038/360361a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/360361a0